Pankaj Patel

Pharmacy grad's generics outfit Cadila Healthcare was taken to court by Swiss giant Roche for selling a clone of its popular breast cancer drug Herceptin in India. Cadila said it had secured regulatory approval. Its shares, which suffered a hit earlier when it received a warning from the U.S. FDA for violating manufacturing standards at one its factories, recovered after a positive report by the health regulator. In June Cadila acquired 2 drugs in the pipeline from Teva Pharmaceutical's U.S. portfolio.